Literature DB >> 750827

Incidence and severity of experimental allergic encephalomyelitis and cerebral prostaglandin synthesis in essential fatty acid deficient and aspirin-treated rats.

P G Weston, P V Johnston.   

Abstract

Experimental allergic encephalomyelitis (EAE) was induced in rats of the Lewis strain fed diets adequate or deficient in essential fatty acids (EFA). After induction of the disease, the diets were supplemented with aspirin (3.75 g/kg diet), and the effects of the drug on the course of EAE and on the synthesis of prostaglandin F (PGF) by brain slices from diseased animals and their Freund controls were examined. Aspirin supplementation delayed the onset of EAE in both dietary groups. EFA-deficient rats experienced an incidence and severity of the disease similar to that of aspirin-free, EFA-deficiet rats, while the EFA-adequate group showed a greater severity but not an increased incidence, compared to aspirin-free controls. Aspirin treatment led to an increased PGF production by brain slices from rats on either diet and not subjected to an immunochallenge. When the diet was deficient in EFA, challenge with antigen plus adjuvant or adjuvant alone tended to decrease PGF synthesis by brain slices, and when the diet was adequate in EFA, immunochallenge caused a marked depression on PGF synthesis. It was concluded that the PG synthetase inhibitor aspirin can alter the course of EAE in the rat, providing further evidence that PGs or related metabolites may be involved in the immune response in this disease.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 750827     DOI: 10.1007/bf02533841

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  20 in total

1.  Inhibitory action of aspirin on DNA synthesis in phytohaemagglutinin-stimulated human lymphocytes.

Authors:  C D Dewse
Journal:  J Pharm Pharmacol       Date:  1977-07       Impact factor: 3.765

2.  Rapid determination of salicylate in biological fluids.

Authors:  P TRINDER
Journal:  Biochem J       Date:  1954-06       Impact factor: 3.857

3.  Prevention of experimental allergic encephalomyelitis by various agents.

Authors:  L C KOLB; A G KARLSON; G P SAYRE
Journal:  Trans Am Neurol Assoc       Date:  1952

4.  Inhibition of prostaglandin synthesis in man.

Authors:  M Hamberg
Journal:  Biochem Biophys Res Commun       Date:  1972-11-01       Impact factor: 3.575

5.  Aspirin selectively inhibits prostaglandin production in human platelets.

Authors:  J B Smith; A L Willis
Journal:  Nat New Biol       Date:  1971-06-23

6.  The effects of antiinflammatory drugs on the production of prostaglandins in vivo.

Authors:  G A Higgs; E A Harvey; S H Ferreira; J R Vane
Journal:  Adv Prostaglandin Thromboxane Res       Date:  1976

7.  Cerebral prostaglandin synthesis during the dietary and pathological stresses of essential fatty acid deficiency and experimental allergic encephalomyelitis.

Authors:  P G Weston; P V Johnston
Journal:  Lipids       Date:  1978-06       Impact factor: 1.880

8.  Allergic encephalomyelitis induced by brain antigen after deficiency in polyunsaturated fatty acids during myelination. Is multiple sclerosis a nutritive disorder?

Authors:  J Clausen; J Moller
Journal:  Acta Neurol Scand       Date:  1967       Impact factor: 3.209

9.  Prostaglandin biosynthesis and metabolism in rat brain slices.

Authors:  C A Leslie
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1976-07

10.  Aspirin effects on lymphocyte cyclic AMP levels in normal human subjects.

Authors:  D E Snider; C W Parker
Journal:  J Clin Invest       Date:  1976-08       Impact factor: 14.808

View more
  2 in total

Review 1.  Role of prostaglandins in neuroinflammatory and neurodegenerative diseases.

Authors:  Isabel Vieira de Assis Lima; Leandro Francisco Silva Bastos; Marcelo Limborço-Filho; Bernd L Fiebich; Antonio Carlos Pinheiro de Oliveira
Journal:  Mediators Inflamm       Date:  2012-06-18       Impact factor: 4.711

Review 2.  Aspirin and multiple sclerosis.

Authors:  Sheila Tsau; Mitchell R Emerson; Sharon G Lynch; Steven M LeVine
Journal:  BMC Med       Date:  2015-06-29       Impact factor: 8.775

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.